摘要
胃肠道肿瘤是我国的常见恶性肿瘤．严重影响中国人的健康。随着肿瘤分子标志物研究的深入和新型抗肿瘤药物的开发应用，胃肠道肿瘤的治疗模式正在不断发生着变化．越来越多的分子靶向药物如曲妥珠单抗、西妥昔单抗和贝伐单抗等开始应用于临床。基于肿瘤分子分型制定适合患者的个体化治疗策略必将使更多的患者从治疗中获得益处，是未来胃肠道肿瘤治疗的必然趋势。
Gastrointestinal cancer is one of the most common malignant tumors in China which affects people health seriously. Along with the investigation of the cancer molecular markers and the application of novel target agents, the therapeutic modalities for gastrointestinal cancers have been changing gradually. More and more target drugs, such as trastuzumab, cetuximab, bevacizumab, have been used in clinical practice. The individualized therapybased on the molecular classification will benefit more patients and is the inevitable trend of gastrointestinal cancer treatments in the future.
出处
《中华胃肠外科杂志》
CAS
CSCD
2014年第1期6-9,共4页
Chinese Journal of Gastrointestinal Surgery
基金
基金项目：国家973课题（2010CB529303）
关键词
胃肠道肿瘤
分子标志物
个体化治疗
Gastrointestinal neoplasms
Molecular markers
Individualized therapy
